Evidence map›Paper›PMID 17726226›Full record

ArticleJournal of molecular neuroscience : MN2007

The combination of homozygous MTHFR 677T and angiotensin II type-1 receptor 1166C variants confers the risk of small-vessel-associated ischemic stroke.

Zoltan Szolnoki, Anita Maasz, Lili Magyari, Katalin Horvatovich, Bernadett Farago, Ferenc Somogyvari, Andras Kondacs, Mihaly Szabo, Anita Bodor, Ferenc Hadarits and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Evaluation of the MTHFR A1298C variant in leukoaraiosis.Journal of molecular neuroscience : MN · 2012
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zoltan SzolnokiDepartment of Neurology and Neurophysiology, Pandy Kalman County Hospital, Gyula. szolnoki99@hotmail.com
Anita Maasz
Lili Magyari
Katalin Horvatovich
Bernadett Farago
Ferenc Somogyvari
Andras Kondacs
Mihaly Szabo
Anita Bodor
Ferenc Hadarits
Bela Melegh

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have suggested that both angiotensin II type-1 receptor (AT1R) 1166C and methylenetetrahydrofolate reductase (MTHFR) 677T variants can have disadvantageous effects on the small-vessel circulation under certain conditions. The purpose of this study was to analyze the possible consequences of the simultaneous distribution of these two genetic variants in different types of ischemic stroke. The genetic and clinical data on 357 ischemic stroke patients and 263 control subjects were analyzed by using univariate and logistic statistical approaches. Neither the MTHFR 677T nor the AT1R 1166C genetic variant alone conferred the risk of any subtype of ischemic stroke. The combination of the homozygous MTHFR 677TT genotype and at least one AT1R 1166C allele occurred more frequently in the ischemic stroke patients (8.68%) than in the controls (4.56%, p < 0.05). Specific subclassification of the patients revealed an accumulation of this combination in small-vessel-associated ischemic stroke (12.2%, p < 0.01); multivariate logistic regression analysis of the data confirmed this association, with an odds ratio of 2.66 (95% confidence interval, 1.28-7.89; p < 0.05). These findings suggest that the combination of these two genetic factors can contribute to the development of small-vessel cerebral infarcts. Although the exact mechanism of action is not known, addition of the unfavourable effects on the endothelial function can be presumed.

Indexed as

Polymorphism, Single NucleotideAllelesGenetic Predisposition to DiseaseHumansMethylenetetrahydrofolate Reductase (NADPH2)Multivariate AnalysisReceptor, Angiotensin, Type 1Risk FactorsStrokeMethylenetetrahydrofolate Reductase (NADPH2)Receptor, Angiotensin, Type 1

Identifiers

PMID17726226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.